Inorial (Bilastine)

Bilastine is a selective peripheral H1‑receptor antagonist. By binding to H1 receptors on mast cells, basophils and other target cells, it prevents histamine from attaching and triggering the cascade that leads to vasodilation, increased vascular permeability and sensory nerve activation. This inhibition reduces the classic allergic symptoms without crossing the blood‑brain barrier significantly.

The dosage of Inorial is determined by the prescribing clinician based on the patient’s age, weight, renal function and the severity of the allergic condition. In most cases, a single daily oral dose is recommended, but the exact amount and timing must follow the healthcare professional’s instructions.

Safety data for bilastine in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers generally advise caution and may prefer alternative antihistamines with established safety profiles.

To request Inorial, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any required cold‑chain or import documentation—before finalising the order.

Compared with first‑generation antihistamines, bilastine offers a non‑sedating profile because it minimally penetrates the central nervous system. Relative to other second‑generation agents, it has a similar efficacy for allergic rhinitis and urticaria, but its pharmacokinetic profile may provide a longer duration of action and fewer drug‑food interactions, making it a convenient once‑daily option.

Inorial should be stored at room temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or near heat sources. Do not use the medication after the expiry date printed on the label.

Inorial is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but patients should avoid simultaneous intake of fruit juices such as grapefruit or orange, which may reduce absorption. The tablet should be consumed at the same time each day to maintain consistent plasma levels.

Although generally well tolerated, Inorial can cause rare but serious adverse reactions, including anaphylaxis, angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like swelling of the face or throat, rash, blistering, or irregular heartbeat. Prompt discontinuation and medical evaluation are essential.

Inorial is contraindicated in individuals with known hypersensitivity to bilastine or any of the tablet’s excipients. Caution is advised for patients with severe renal impairment, as clearance may be reduced. It should also be avoided in patients taking potent CYP3A4 or P‑glycoprotein inhibitors without medical supervision, and in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.